EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Drug Therapy for Melanoma: Current Updates and Future Prospects

Hiroshi Kato iD

Cancers · 26.01.2026 · 18 (3) · 382

DOI: 10.3390/cancers18030382 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 26.01.2026. Verfasst von Hiroshi Kato. Beteiligte Einrichtung: Department of Geriatric and Environmental Dermatology, Graduate School of Medical Sciences, Nagoya City University, 1-Kawasumi, Mizuho-cho, Mizuho-ku…. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Melanoma was once considered ‘incurable’; however, drug therapy for the condition has dramatically transformed with the advent of immune checkpoint inhibitors and molecular targeted therapies. In this review, we summarize the published literature on melanoma drug therapy, presenting the current landscape of melanoma treatments, and discuss potential future transformations in melanoma therapy. Although the prognosis of advanced-stage melanoma had been extremely poor in the past, new-age immunotherapy has made long-term survival possible. Several immunotherapies and their combinations, as well as personalized vaccines, cell therapies, and intratumoral agents, have been tested with success; however, adverse toxicities have also been detected. Therefore, patient selection and management are critical. Furthermore, new approaches to overcome the limitations of the current treatments are also being developed. To implement these therapies clinically, guideline-recommended treatment algorithms should be followed while optimizing the therapies by considering factors such as presence of BRAF mutations which may lead to treatment resistance, increased disease burden/progression rate, toxicity tolerance, and the presence of brain metastases. In practice, the choice of the initial therapy should depend on the patient, leading to personalized therapy and minimal adverse effects.

Schlagwörter

Stichwörter der Autor:innen

BRAF/MEK inhibitionimmune checkpoint inhibitorsmelanomatargeted therapytreatment resistance

Autor:innen und Institutionen

  • Department of Geriatric and Environmental Dermatology, Graduate School of Medical Sciences, Nagoya City University, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan.

ORCID-Profile: Hiroshi Kato

Zitieren

APA

Kato, H. (2026). Drug Therapy for Melanoma: Current Updates and Future Prospects. Cancers, 18(3), 382. https://doi.org/10.3390/cancers18030382

Vancouver

Kato H. Drug Therapy for Melanoma: Current Updates and Future Prospects. Cancers. 2026;18(3):382. doi:10.3390/cancers18030382

BibTeX
@article{Kato2026,
  author = {Kato, Hiroshi},
  title = {Drug Therapy for Melanoma: Current Updates and Future Prospects},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {3},
  pages = {382},
  doi = {10.3390/cancers18030382}
}
Kostenlos starten →